Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (VVOS) Revenue
Annual & quarterly revenue history · segment & region breakdown
VVOS · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsVivos Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.02B, an increase of 16.05% year-over-year from $0.02B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.02B | +$0.00B | +16.05% |
| 2024-12-31 | $0.02B | +$0.00B | +8.91% |
| 2023-12-31 | $0.01B | -$0.00B | -13.87% |
| 2022-12-31 | $0.02B | -$0.00B | -5.10% |
| 2021-12-31 | $0.02B | +$0.00B | +29.23% |
| 2020-12-31 | $0.01B | +$0.00B | +14.68% |
| 2019-12-31 | $0.01B | +$0.01B | +200.43% |
| 2018-12-31 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Vivos Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Vivos Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Vivos Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
VVOS revenue · 4 questionsVVOS's trailing twelve-month (TTM) revenue is $0.02B. That is an increase of 16.05% year-over-year from $0.02B in FY2025.
▸ Source: FMP · Vivos Therapeutics, Inc. SEC filings · GAAP · Vivos Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026